FDA "Complete Response" On Toremifene Moves The Goal Posts, GTx CEO Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GTx was taken by surprise with FDA's decision to issue a "complete response" letter for the firm's selective estrogen receptor modulator toremifene 80 mg - a drug whose clinical development program was designed with the agency's help under a Special Protocol Assessment